Zimmer Biomet Holdings’ (ZBH) “Buy” Rating Reiterated at Jefferies Group LLC

Zimmer Biomet Holdings, Inc. (NYSE:ZBH)‘s stock had its “buy” rating reissued by research analysts at Jefferies Group LLC in a research note issued on Friday. They currently have a $136.00 price objective on the medical equipment provider’s stock. Jefferies Group also issued estimates for Zimmer Biomet Holdings’ Q4 2017 earnings at $2.10 EPS, FY2017 earnings at $8.03 EPS, Q1 2018 earnings at $2.04 EPS, Q2 2018 earnings at $2.02 EPS, Q3 2018 earnings at $1.94 EPS, Q4 2018 earnings at $2.25 EPS and FY2018 earnings at $8.25 EPS.

A number of other research analysts have also weighed in on the stock. BMO Capital Markets reissued a “buy” rating and issued a $136.00 target price on shares of Zimmer Biomet Holdings in a report on Tuesday, July 11th. Wells Fargo & Company reissued a “market weight” rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Morgan Stanley raised their target price on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 17th. Stifel Nicolaus reissued a “hold” rating and issued a $125.00 target price on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Finally, Zacks Investment Research lowered shares of Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $135.00.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The company had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.83 billion. During the same period last year, the business earned $1.79 earnings per share. The company’s quarterly revenue was down .8% compared to the same quarter last year.

WARNING: This story was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/03/zimmer-biomet-holdings-zbh-buy-rating-reiterated-at-jefferies-group-llc.html.

Several large investors have recently added to or reduced their stakes in ZBH. Bronfman E.L. Rothschild L.P. increased its stake in shares of Zimmer Biomet Holdings by 25.3% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 167 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Zimmer Biomet Holdings by 3.9% during the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 33 shares during the period. Parallel Advisors LLC increased its stake in shares of Zimmer Biomet Holdings by 20.8% during the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares during the period. IHT Wealth Management LLC increased its stake in shares of Zimmer Biomet Holdings by 28.4% during the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares during the period. Finally, BB&T Investment Services Inc. purchased a new position in shares of Zimmer Biomet Holdings during the second quarter valued at $144,000. Institutional investors and hedge funds own 85.26% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet Holdings (NYSE:ZBH)

What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit